The text provides unaudited financial information for Bristol-Myers Squibb Company for the three months ended March 31, 2023, detailing the company's consolidated statements of earnings, comprehensive income, balance sheets, and cash flows. It mentions the company's single-segment focus on the healthcare sector, with revenues from net product sales, alliances, and other sources, along with key financial figures such as earnings before taxes, net earnings, and cash flows. The information includes details on debt, liabilities, equity, and recent accounting standards adoption, revenue breakdowns, GTN adjustments, and alliances. It also discusses financial instruments and strategies like cash flow hedges, net investment hedges, fair value hedges, financing arrangements, receivables, inventories, property, plant, and equipment. The text showcases the company's financial status reflected in short-term debt, long-term debt, supplemental financial information, impairment charges, changes in fair value, and notional values of outstanding derivatives.
The provided text discusses the management's discussion and analysis of financial conditions and operational results for a pharmaceutical company, focusing on areas such as strategy, recent approvals in the EU and Japan, revenue breakdown, market factors, product developments, financial measures, expenses, income taxes, financial position, liquidity, capital resources, cash flows, critical accounting policies, forward-looking statements, and disclosures. It elaborates on various product launches, financial results, operational activities, and highlights forward-looking aspects along with an emphasis on non-GAAP financial measures and customary financial analysis metrics to provide a holistic view of the company's standing and future direction.
The text provides a brief reference to the discussion on market risk in the company's 2022 Form 10-K under "Item 7A. Quantitative and Qualitative Disclosures about Market Risk." It suggests referring to that section for further details on the company's market risk analysis.
Management evaluated the effectiveness of its disclosure controls and procedures as of March 31, 2023, finding them to be effective. No changes occurred in the Company's internal control over financial reporting during the quarter that had, or are likely to have, a significant impact on the internal control over financial reporting.
The text provides guidance on where to find information related to legal proceedings, referring readers to "Item 1. Financial Statements—Note 18. Legal Proceedings and Contingencies" within the interim consolidated financial statements. This information is incorporated by reference in the text being examined.
The text states that there have been no significant changes in the risk factors disclosed in the Company's 2022 Form 10-K.
The text discusses the unregistered sales of equity securities and the use of proceeds within a specific time period. It includes a table summarizing the number of shares purchased, the average price paid per share, and the total number of shares purchased as part of publicly announced programs. It also mentions the remaining dollar value of shares that may be purchased under the programs. The text further explains that the repurchases include shares surrendered to satisfy tax withholding obligations and authorized by the Board of Directors for stock buybacks, with remaining capacity of approximately $6.9 billion as of March 31, 2023.
I'm sorry, but I haven't received any text from you yet. Could you please provide me with the text you would like me to summarize?
I am ready to receive the text parts for summarization.
I'm sorry, but I cannot provide a summary without the text that you are referring to. Please provide me with the text that you would like summarized.
The text provided includes information on various exhibits listed with descriptions in a document, as well as a summary of certain terms and abbreviations defined in the text. It also includes signatures at the end of the document by the Chairman of the Board and Chief Executive Officer, Giovanni Caforio, M.D., and the Chief Financial Officer, David V. Elkins, both on behalf of Bristol-Myers Squibb Company, in accordance with the Securities Exchange Act of 1934.
